Breaking News

Tweet TWEET

Cardiome Announces Commercialization Partnership For BRINAVESS™ In Select European Markets

Cardiome Announces Commercialization Partnership For BRINAVESS™ In Select 
European Markets 
NASDAQ: CRME TSX: COM 
VANCOUVER, July 3, 2013 /CNW/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: 
COM) today announced an agreement with AOP Orphan Pharmaceuticals AG, 
headquartered in Vienna, Austria, to commercialize BRINAVESS™ (vernakalant 
intravenous) in select European markets. AOP Orphan will support Cardiome in 
obtaining product registrations required for the marketing and sale of 
BRINAVESS in the AOP Orphan countries and will actively call on customers to 
promote the product. Under terms of the agreement, AOP Orphan has agreed to 
specific annual commercial goals for BRINAVESS. Financial details of the 
agreement were not disclosed. 
"Execution of the BRINAVESS commercial agreement with AOP Orphan fulfills a 
key objective in Cardiome's European commercialization strategy," said William 
Hunter, M.D., CEO of Cardiome. "Through the agreement, additional physicians 
and patients beyond the reach of our current sales force will have access to 
BRINAVESS. We are very pleased to have partnered with such a well-known, 
highly experienced and respected company." 
"We are excited to partner and work with Cardiome, and to add BRINAVESS to our 
cardiovascular drug portfolio," said Rudolf Widmann, Ph. D., CEO of AOP 
Orphan. "The synergies that exist between BRINAVESS and our cardiovascular 
franchise should enable us to build on our existing customer base by offering 
a complementary product and develop new customer relationships which are key 
to our future growth." 
The initial term of this commercial agreement begins July 1, 2013 for the 
duration of three years and is renewable on an annual basis, or longer, 
thereafter. The AOP Orphan countries include: Austria; Bosnia and Herzegovina; 
Bulgaria; Croatia; Czech Republic; Estonia; Hungary; Kazakhstan; Latvia; 
Lithuania; Montenegro; Macedonia; Poland; Romania; Serbia; Slovakia; Slovenia; 
Switzerland; and Ukraine. 
About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the 
discovery, development and commercialization of new therapies that will 
improve the health of patients around the world. Cardiome has one marketed 
product, BRINAVESS™ (vernakalant IV), approved in Europe and other 
territories for the rapid conversion of recent onset atrial fibrillation to 
sinus rhythm in adults. 
Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock 
Exchange (COM). For more information, please visit our web site at 
www.cardiome.com. 
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking statements 
within the meaning of the Private Securities Litigation Reform Act of 1995 or 
forward-looking information under applicable Canadian securities legislation 
that may not be based on historical fact, including without limitation 
statements containing the words "believe", "may", "plan", "will", "estimate", 
"continue", "anticipate", "intend", "expect" and similar expressions. 
Forward- looking statements may involve, but are not limited to, comments with 
respect to our objectives and priorities for the remainder of 2013 and beyond, 
our strategies or future actions, our targets, expectations for our financial 
condition and the results of, or outlook for, our operations, research and 
development and product and drug development. Such forward-looking statements 
involve known and unknown risks, uncertainties and other factors that may 
cause the actual results, events or developments to be materially different 
from any future results, events or developments expressed or implied by such 
forward-looking statements. Many such known risks, uncertainties and other 
factors are taken into account as part of our assumptions underlying these 
forward-looking statements and include, among others, the following: general 
economic and business conditions in the United States, Canada, Europe, and the 
other regions in which we operate; market demand; technological changes that 
could impact our existing products or our ability to develop and commercialize 
future products; competition; existing governmental legislation and 
regulations and changes in, or the failure to comply with, governmental 
legislation and regulations; availability of financial reimbursement coverage 
from governmental and third-party payers for products and related treatments; 
adverse results or unexpected delays in pre-clinical and clinical product 
development processes; adverse findings related to the safety and/or efficacy 
of our products or products; decisions, and the timing of decisions, made by 
health regulatory agencies regarding approval of our technology and products; 
the requirement for substantial funding to expand commercialization 
activities; and any other factors that may affect our performance. In 
addition, our business is subject to certain operating risks that may cause 
any results expressed or implied by the forward-looking statements in this 
presentation to differ materially from our actual results. These operating 
risks include: our ability to attract and retain qualified personnel; our 
ability to successfully complete pre-clinical and clinical development of our 
products; changes in our business strategy or development plans; intellectual 
property matters, including the unenforceability or loss of patent protection 
resulting from third-party challenges to our patents; market acceptance of our 
technology and products; our ability to successfully manufacture, market and 
sell our products; the availability of capital to finance our activities; and 
any other factors described in detail in our filings with the Securities and 
Exchange Commission available at www.sec.gov and the Canadian securities 
regulatory authorities at www.sedar.com. Given these risks, uncertainties and 
factors, you are cautioned not to place undue reliance on such forward-looking 
statements and information, which are qualified in their entirety by this 
cautionary statement. All forward-looking statements and information made 
herein are based on our current expectations and we undertake no obligation to 
revise or update such forward-looking statements and information to reflect 
subsequent events or circumstances, except as required by law. 
Cardiome Investor Relations (604) 676-6993 or Toll Free: 1-800-330-9928 
Email:ir@cardiome.com 
SOURCE: Cardiome Pharma Corp. 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/July2013/03/c5078.html 
CO: Cardiome Pharma Corp.
ST: British Columbia
NI: MTC ORDER  
-0- Jul/03/2013 16:00 GMT